A clinical trial from India raises the possibility of huge cost savings by using ultralow immunotherapy doses in the treatment of head and neck cancer.
Immunotherapy combinations based on nivolumab entail lower costs for grade 3/4 adverse events than those using pembrolizumab, a finding that could inform treatment decisions.
One of the problems with the new subgroup of HER2 low tumors is that using current assays to measure low levels "is like weighing mice on a scale built for elephants," says one expert.
The combination of salvage irinotecan, vincristine, and anlotinib may be another option for refractory epithelioid sarcoma. The study was published as a preprint and has not yet been peer reviewed.